Phase Ｉ/Ⅱ Sturdy on Antiangiogenic Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer

NCT00655785 Phase 1/Phase 2 COMPLETED

The purpose of this study is to evaluate the safety, and tolerability of HLA-A\*2402 restricted epitope peptide VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in combination with gemcitabine

Details

Lead sponsor	Fukushima Medical University
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	17
Start date	2007-09
Completion	2013-03

Conditions

• Pancreatic Cancer

Interventions

• VEGFR1-1084, VEGFR2-169
• Gemcitabine

Primary outcomes

• toxicities as assessed by NCI-CACAE ver3) — 3 months

Countries

Japan